CORONA Remedies begins additional commercial production at Bhayla facility

Business Updates View source PDF Explain this filing

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.6%Reaction day

₹1369.50

prior close

₹1355.00

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.4%-2.9% vs market

Pharmaceuticals peers, median of 155sector+0.7%-2.3% vs sector

On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.0

15m

-0.5

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.6+1.4-2.9+0.7-2.3

Next day

-0.6+1.4-2.0+0.7-1.3

-1.8+0.9-2.7+0.6-2.4

-0.6+0.3-1.0+0.0-0.7

+0.6-0.4+1.1-0.7+1.3

+1.3-0.5+1.8-0.8+2.1

+2.6+1.1+1.5-0.0+2.6

15d

+4.8-2.5+7.3-2.1+6.9

+1.1-6.1+7.3-6.2+7.3

+15.2-2.8+18.0-5.6+20.8

+15.4-14.9+30.3-13.7+29.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

CORONA Remedies has started additional commercial production of tablets and capsules at its Bhayla manufacturing facility from December 22, 2025. The plant currently has installed capacity of 852.80 million units, with actual production of 561.49 million, reflecting 93.58% capacity utilization. The expansion will add 400 million to installed capacity and 240 million to available capacity, funded entirely through internal accruals. The move supports upcoming market demand and improves supply chain agility.

Likely market impact

Adds about 40% to available capacity at a high-utilization plant, supporting future revenue potential with no debt funding.